A Study to Investigate Ubamatamab With and Without REGN7075 in Adult Participants With Advanced/Metastatic Non-Small Cell Lung Cancer (NSCLC)

This study will evaluate two study drugs called ubamatamab and REGN7075, to see if they can help treat advanced or metastatic Non-Small Cell Lung Cancer (NSCLC), and sarilumab, to evaluate to see if it can help with immune-related side effects from ubamatamab. The study is looking at: * How well ubamatamab and REGN7075 works * The side effects that ubamatamab and REGN7075 might cause * How much ubamatamab and REGN7075 is in the blood at different times * If the body makes antibodies to ubamatamab and/or REGN7075, this may cause the ubamatamab to not work as well

Trial Details

NCT ID

NCT07154290

Phase

PHASE2

Sponsor

Regeneron Pharmaceuticals

Status

RECRUITING

Cancer Type

Non-Small Cell (NSCLC) Lung Cancer

Interventions

Ubamatamab
REGN7075
Sarilumab

Locations (sample)

Goodyear, Arizona, United States|33.43532,-112.35821
Irvine, California, United States|33.66946,-117.82311
Baltimore, Maryland, United States|39.29038,-76.61219
Knoxville, Tennessee, United States|35.96064,-83.92074

Key Eligibility Criteria

Has histologically or cytologically confirmed diagnosis of advanced (stage IIIB not amenable to definitive chemoradiotherapy or stage IIIC) or meta…
Has received appropriate first line standard of care treatment for advanced or metastatic NSCLC, as described in the protocol
If platinum doublet chemotherapy was not administered as first line therapy, it is required in a later line of therapy prior to enrollment unless t…
Has tumor tissue (archival or fresh) available for testing MUC16 expression by immunohistochemistry inclusion (IHC), as described in the protocol

For full eligibility, visit ClinicalTrials.gov.

Check If You May Be Eligible

Trialify translates complex eligibility criteria into plain yes-or-no questions to help you understand if this trial might be right for you.

Find Non-Small Cell (NSCLC) Lung Cancer Trials on Trialify →